According to the National Institutes of Health as many as 7.5 million Americans have psoriasis, a non-contagious, lifelong skin disease. The most common form, plaque psoriasis, appears as raised, red patches or lesions covered with a silvery white buildup of dead skin cells, called scale. Psoriasis varies from person to person, both in severity and how it responds to treatment. Psoriasis is now recognized to be a disease that can be modified by drugs that inhibit TNF-alpha signaling. Current treatment for severe psoriasis includes biologic drugs that are costly, potentially toxic, and require intravenous administration. In addition, steroids often work for patients with mild-to-moderate psoriasis, yet they carry side effects and are generally not recommended for long-term use.
About Synvista Therapeutics
Synvista Therapeutics is a biopharmaceutical company developing small molecule drugs to treat and prevent cardiovascular disease and to treat nephropathy in people with diabetes. The Company has identified several product candidates that it believes represent novel approaches to some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. These compounds metabolize lipid peroxides and have the potential to limit myocardial damage subsequent to a myocardial infarction. The Company is developing a clinical diagnostic test, based on cardiovascular risk assessment using Haptoglobin characterization, to identify patients at high risk for cardiovascular complications of diabetes.
Synvista Therapeutics also is developing alagebrium, a proposed breaker
of AGEs for the treatment of diastolic heart failure. This disease
represents a rapidly growi
|SOURCE Synvista Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved